Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TVI Brain 1

X
Drug Profile

TVI Brain 1

Alternative Names: TVI-Brain-1; Vaccine-enhanced adoptive T cell therapy - TVAX Biomedical; VACT - TVAX Biomedical

Latest Information Update: 10 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TVAX Biomedical
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Astrocytoma; Glioblastoma; Glioma

Most Recent Events

  • 15 Sep 2023 Phase-IIb clinical trials in Glioblastoma (First-line therapy) in USA (IV) (NCT05685004)
  • 07 Jul 2023 TVAX Biomedical initiates an expanded-access programme for Glioblastoma (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in USA (NCT05936216)
  • 01 Feb 2023 Phase-II development in Glioma (Recurrent, Second-line therapy or greater) is ongoing in USA (IV) (TVAX Biomedical pipeline, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top